Consensus Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
6.85 ^USD	+0.88%		-2.14%	-6.42%

Mar. 26	Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	MT
Mar. 26	Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	CI

Evolution of the average Target Price on Verrica Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

cfdad97dad.aTwv3_Xw0dZxsRV_0PJ9gGjFPfpZViNcE0Ahw3aEzN8.IGp1hqq2ueYy9n8mm7g_2RK1dZsWHFcffDBF8TPVtI8MVBavvrrnghfbZg~f8e14b9cf66a86dba7f68486ebfa30f4

Analyst Recommendations on Verrica Pharmaceuticals Inc.

HC Wainwright Adjusts Verrica Pharmaceuticals Price Target to $13 From $12, Maintains Buy Rating	Mar. 01	MT
Needham Adjusts Verrica Pharmaceuticals' Price Target to $8 From $10, Maintains Buy Rating	Nov. 10	MT
HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $12 From $11, Maintains Buy Rating	23-07-27	MT
RBC Boosts Price Target on Verrica Pharmaceuticals to $14 From $11 Amid 'Improved Company Positioning,' Keeps Outperform, Speculative Risk	23-07-25	MT
Needham Upgrades Verrica Pharmaceuticals to Buy From Hold, Price Target is $10	23-07-25	MT
Jefferies Initiates Verrica Pharmaceuticals at Buy With $10 Price Target	23-03-22	MT
Verrica Pharmaceuticals Upgraded by RBC to Outperform From Sector Perform, Price Target Boosted to $11 From $4, Speculative Risk Kept	23-02-13	MT
HC Wainwright Adjusts Verrica Pharmaceuticals' Price Target to $12 From $20, Maintains Buy Rating	22-05-31	MT
Needham & Co Downgrades Verrica Pharmaceuticals to Hold From Buy	22-05-25	MT
Needham Downgrades Verrica Pharmaceuticals to Hold From Buy	22-05-25	MT
Verrica Pharmaceuticals Shares Plumb New Depths After VP-102 Setback	22-05-25	DJ
RBC Downgrades Verrica Pharmaceuticals to Sector Perform From Outperform Amid Setback for VP-102, Cuts Price Target to $4 From $16; Speculative Risk Qualifier Kept	22-05-25	MT
Brookline Capital Markets Starts Verrica Pharmaceuticals at Buy With $20 Price Target	22-03-10	MT
Needham Adjusts Verrica Pharmaceuticals' Price Target to $18 from $20, Reiterates Buy Rating	22-03-03	MT
VERRICA PHARMACEUTICALS : HC Wainwright Cuts Price Target on Verrica Pharmaceuticals to $20 From $24, Maintains Buy Rating	21-09-22	MT
VERRICA PHARMACEUTICALS : Northland Securities Adjusts Verrica Pharmaceuticals PT to $18 From $19, Maintains Outperform Rating	21-09-21	MT
VERRICA PHARMACEUTICALS : Needham Cuts Price Target on Verrica Pharmaceuticals to $20 from $22, Keeps Buy Rating	21-09-21	MT
VERRICA PHARMACEUTICALS : RBC Cuts Price Target on Verrica Pharmaceuticals to $16 From $19 as FDA Notes Facility Issues; Outperform, Speculative Risk Kept	21-09-21	MT
VERRICA PHARMACEUTICALS : Northland Adjusts Price Target on Verrica Pharmaceuticals to $19 From $24, Keeps Outperform Rating	21-06-01	MT
VERRICA PHARMACEUTICALS : Initiated at Outperform With Speculative Risk by RBC, Price Target Set at $19/Share	21-05-14	MT
VERRICA PHARMACEUTICALS : HC Wainwright & Co. Adjusts Price Target on Verrica Pharmaceuticals to $24 From $21, Maintains Buy Rating	21-03-08	MT
VERRICA PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $21 From $18, Maintains Buy Rating	20-12-24	MT